A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form. Chromatogram was run through Denali C18 column (150 mm × 4.6 mm, 5 µm); mobile phase containing buffer and acetonitrile in the ratio of 50:50 was pumped through column at a flow rate of 1 ml/min [Buffer: 0.1% at pH 2.2, temperature 30°C]. Optimized wavelength was 272 nm. Retention times of Emtricitabine, Bictegravir and Tenofovir alafenamide were found to be 2.303, 3.219 and 3.754 min respectively. The %RSD of the Emtricitabine, Bictegravir and Tenofovir alafenamide were found to be 0.7, 0.8 and 0.4, respectively. The %recovery was obtained as 99.89%, 100.65% and 100.38% for Emtricitabine, Bictegravir and Tenofovir alafenamide, respectively. This method was accurate, precise and sensitive; hence, could be employed for routine quality control of Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical industries and drug testing laboratories.
A novel method was developed for the simultaneous estimation of the doravirine, lamivudine, and tenofovir disoproxil fumarate in the pharmaceutical dosage form.The chromatogram was run through an Ascentis C18 column (150 Â 4.6 mm, 2.7 μm), with the mobile phase consisting of a phosphate buffer and acetonitrile in the ratio of 50:50 (v/v). The mobile phase was pumped through the column at a flow rate of 1 mL/min. The column temperature was maintained at 30 C. The optimized wavelength for doravirine, lamivudine, and tenofovir disoproxil fumarate was 230.0 nm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.